3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
20
Pain, Postoperative
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Neoplasms
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
4
Prostatic Neoplasms
3
Myoma
3
Leiomyoma
3
Head and Neck Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Agnosia
3
Stomatitis
2
Skin Neoplasms
2
Postoperative Hemorrhage
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Hemorrhage
2
Fatigue
2
Colonic Neoplasms
2
Chronic Pain
2
Carcinoma, Hepatocellular
2
Water-Electrolyte Imbalance
1
Vulvodynia
1
Uterine Cervical Neoplasms
1
Interventions
Imatinib Mesylate
41
Sunitinib
17
nilotinib
12
regorafenib
10
ripretinib
6
avapritinib
6
Leucovorin
3
Ipilimumab
3
Gemcitabine
3
Dasatinib
3
CTLA-4 Antigen
3
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
3
pexidartinib
2
Paclitaxel
2
Oxaliplatin
2
Midazolam
2
Irinotecan
2
Fluorouracil
2
Floxuridine
2
Erlotinib Hydrochloride
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
Capecitabine
2
Biopsy, Fine-Needle
2
Bevacizumab
2
vatalanib
1
umbralisib
1
trametinib
1
tinostamustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Stromal Tumors
×
Sodium Chloride
×
Clear all
NCT01265810
2017-11-13
COMTT
Impaqtt Foundation
Phase 3
Completed
64 enrolled